LGVN (Longeveron) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LGVN Longeveron Inc LGVN
45 GF Score
Price $0.61
GF Value $0.38
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Longeveron Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

LGVN
45GF Score
Longeveron Inc LGVN
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Longeveron (LGVN) Overvalued in 2026?

Based on GuruFocus' analysis, Longeveron stock appears to be overvalued. The current stock price of $0.61 is trading 60.8% above its estimated GF Value™ of $0.38. GuruFocus considers Longeveron to be Significantly Overvalued.

Key valuation signals for LGVN:

  • Dividends Received:
  • GF Value™: $0.38 vs. price of $0.61 (60.8% above fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the LGVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Longeveron Business Description

Address 1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
45GF Score

Get the complete analysis for LGVN

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.61
Price
$0.38
GF Value